Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: Potential relevance to the pathophysiology of Parkinson's disease

Journal of Molecular Neuroscience

Volumn 46, Issue 1, 2012, Pages 177-183

  Melcangi, Roberto Cosimo ^a   Caruso, Donatella ^a   Levandis, Giovanna ^b   Abbiati, Federico ^a   Armentero, Marie Therese ^b   Blandini, Fabio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

6 Hydroxydopamine; Cerebral cortex; Dihydroprogesterone; Isopregnanolone; Pregnenolone; Striatum

Indexed keywords

17ALPHA ESTRADIOL; 20ALPHA DIHYDROPROGESTERONE; 3ALPHA DIOL; ANDROSTANOLONE; ELTANOLONE; ESTRADIOL; ISOPREGNANOLONE; OXIDOPAMINE; PRASTERONE; PREGNENOLONE; PROGESTERONE; STEROID; TESTOSTERONE; TETRAHYDROPROGESTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; LIQUID CHROMATOGRAPHY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RAT; STRIATONIGRAL DEGENERATION; TANDEM MASS SPECTROMETRY;

ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; MALE; NERVE DEGENERATION; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; STEROIDS; SUBSTANTIA NIGRA; SYMPATHOLYTICS;

RATTUS;

EID: 84858826382     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-011-9570-y     Document Type: Article

References (41)

1. Backstrom T, Wahlstrom G, Wahlstrom K, Zhu D, Wang MD (2005) Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats. Eur J Pharmacol 512:15-21 (Pubitemid 40462358)
2. Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6:565-575 (Pubitemid 40942823)
3. Benedetti MD, Maraganore DM, Bower JH et al (2001) Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 16:830-837 (Pubitemid 36041184)
4. Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T (1997) Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy- 5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 764:173-178 (Pubitemid 27380653)
5. Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88 (Pubitemid 30252017)
6. Blandini F, ArmenteroMT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2): S124-S129
7. Bourque M, Dluzen DE, Di Paolo T (2009) Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 30:142-157
8. Callier S, Morissette M, Grandbois M, Di Paolo T (2000) Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 37:245-251 (Pubitemid 30613021)
9. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T (2001) Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41:131-138
10. Caruso D, Scurati S, Maschi O et al (2008a) Evaluation of neuroactive steroid levels by liquid chromatography-tandem mass spectrometry in central and peripheral nervous system: effect of diabetes. Neurochem Int 52:560-568
11. Caruso D, Scurati S, Roglio I, Nobbio L, Schenone A, Melcangi RC (2008b) Neuroactive steroid levels in a transgenic rat model of CMT1A neuropathy. J Mol Neurosci 34:249-253
12. Caruso D, D'Intino G, Giatti S et al (2010) Sex-dimorphic changes in neuroactive steroid levels after chronic experimental autoimmune encephalomyelitis. J Neurochem 114:921-932
13. Ciriza I, Azcoitia I, Garcia-Segura LM (2004) Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J Neuroendocrinol 16:58-63 (Pubitemid 38159394)
14. D'Astous M, Morissette M, Tanguay B, Callier S, Di Paolo T (2003) Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. Synapse 47:10-14 (Pubitemid 35424538)
15. di Michele F, Longone P, Romeo E et al (2003) Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol Sci 24:172-173 (Pubitemid 37304298)
16. Gee KW, Bolger MB, Brinton RE, Coirini H, McEwen BS (1988) Steroid modulation of the chloride ionophore in rat brain: structure-activity requirements, regional dependence and mechanism of action. J Pharmacol Exp Ther 246:803-812
17. Giatti S, D'Intino G, Maschi O et al (2010) Acute experimental autoimmune encephalomyelitis induces sex dimorphic changes in neuroactive steroid levels. Neurochem Int 56:118-127
18. Gillies GE, Murray HE, Dexter D, McArthur S (2004) Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav 78:513-522 (Pubitemid 38906665)
19. Grandbois M, Morissette M, Callier S, Di Paolo T (2000) Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 11:343-346 (Pubitemid 30074646)
20. Huang XF, Luu-The V (2000) Molecular characterization of a first human 3(alpha→beta)-hydroxysteroid epimerase. J Biol Chem 275:29452-29457
21. Luchetti S, di Michele F, Romeo E et al (2006) Comparative nonradioactive RT-PCR assay: an approach to study the neurosteroids biosynthetic pathway in humans. J Neurosci Methods 153:290-298
22. Luchetti S, Bossers K, Frajese GV, Swaab DF (2010) Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol 20:945-951
23. Lundgren P, Stromberg J, Backstrom T, Wang M (2003) Allopregnanolone- stimulated GABA-mediated chloride ion flux is inhibited by 3beta-hydroxy-5alpha- pregnan-20-one (isoallopregnanolone). Brain Res 982:45-53 (Pubitemid 37288797)
24. Marsden CD, Olanow CW (1998) The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol 44:S189-S196 (Pubitemid 28423847)
25. Melcangi RC, Garcia-Segura LM (2010) Sex-specific therapeutic strategies based on neuroactive steroids: In search for innovative tools for neuroprotection. Horm Behav 57:2-11
26. Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG (2008) Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci 65:777-797
27. Morissette M, Al SS, Callier S, Di Paolo T (2008) Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol 290:60-69
28. Nuwayhid SJ, Werling LL (2003) Steroids modulate N-methyl-Daspartate- stimulated [3H] dopamine release from rat striatum via sigma receptors. J Pharmacol Exp Ther 306:934-940 (Pubitemid 37025298)
29. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, San Diego
30. Pesaresi M, Maschi O, Giatti S, Garcia-Segura LM, Caruso D, Melcangi RC (2010) Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats. Horm Behav 57:46-55
31. Quinn NP, Marsden CD (1986) Menstrual-related fluctuations in Parkinson's disease. Mov Disord 1:85-87
32. Ramirez AD, Liu X, Menniti FS (2003) Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77:223-231 (Pubitemid 36667656)
33. Sadri-Vakili G, Janis GC, Pierce RC, Gibbs TT, Farb DH (2008) Nanomolar concentrations of pregnenolone sulfate enhance striatal dopamine overflow in vivo. J Pharmacol Exp Ther 327:840-845
34. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S (1999) The effect of estrogen replacement on early Parkinson's disease. Neurology 52:1417-1421 (Pubitemid 29190534)
35. Schumacher M, Guennoun R, Ghoumari A et al (2007) Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 28:387-439 (Pubitemid 46984826)
36. Schumacher M, Sitruk-Ware R, De Nicola AF (2008) Progesterone and progestins: neuroprotection and myelin repair. Curr Opin Pharmacol 8:740-746
37. Strijks E, Kremer JA, Horstink MW (1999) Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin Neuropharmacol 22:93-97
38. Tsang KL, Ho SL, Lo SK (2000) Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 54:2292-2298
39. Vegeto E, Benedusi V, Maggi A (2008) Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 29:507-519
40. Wang M, He Y, Eisenman LN et al (2002) 3beta -hydroxypregnane steroids are pregnenolone sulfate-like GABA(A) receptor antagonists. J Neurosci 22:3366-3375 (Pubitemid 37465742)
41. Whittaker MT, Gibbs TT, Farb DH (2008) Pregnenolone sulfate induces NMDA receptor dependent release of dopamine from synaptic terminals in the striatum. J Neurochem 107:510-521